These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37051238)

  • 1. Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma.
    Sun L; Liu Z; Wu Z; Ning K; Hu J; Chen Z; Wu Z; Yin X
    Front Immunol; 2023; 14():1113455. PubMed ID: 37051238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of Golgi apparatus-related genes indicates prognosis and immune infiltration in osteosarcoma.
    Zhang J; Liu J; Ding R; Miao X; Deng J; Zhao X; Wu T; Cheng X
    Aging (Albany NY); 2024 Mar; 16(6):5249-5263. PubMed ID: 38460960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtype identification and prognosis stratification based on golgi apparatus-related genes in head and neck squamous cell carcinoma.
    Zhang A; He X; Zhang C; Tang X
    BMC Med Genomics; 2024 Feb; 17(1):53. PubMed ID: 38365684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and validation of Golgi apparatus-related signature for predicting prognosis and immunotherapy response in breast cancer.
    Chen X; Tang P; Kong Y; Chen D; Tang K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):61. PubMed ID: 38300336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signature construction and molecular subtype identification based on immune-related genes for better prediction of prognosis in hepatocellular carcinoma.
    Sun L; Wu Z; Dong C; Yu S; Huang H; Chen Z; Wu Z; Yin X
    BMC Med Genomics; 2023 Jun; 16(1):130. PubMed ID: 37316840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of Golgi apparatus-related genes signature to predict the prognosis and immunotherapy response in gastric cancer patients.
    Liu R; Chu W; Liu X; Hong J; Wang H
    Medicine (Baltimore); 2024 Mar; 103(11):e37439. PubMed ID: 38489711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
    Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
    Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
    Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
    Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
    Xiong X; Song Q; Jing M; Yan W
    Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pyrimidine metabolism-related signature for prognostic and immunotherapeutic response prediction in hepatocellular carcinoma by integrating analyses.
    Zhang S; Qin O; Wu S; Xu H; Huang W; Hailiang S
    Aging (Albany NY); 2024 Mar; 16(6):5545-5566. PubMed ID: 38517376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
    Yu X; Chen P; Yi W; Ruan W; Xiong X
    Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma.
    Zhang X; Zhuge J; Liu J; Xia Z; Wang H; Gao Q; Jiang H; Qu Y; Fan L; Ma J; Tan C; Luo W; Luo Y
    Front Immunol; 2023; 14():1153423. PubMed ID: 37006285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signature construction and molecular subtype identification based on liver-specific genes for prediction of prognosis, immune activity, and anti-cancer drug sensitivity in hepatocellular carcinoma.
    Zhang X; Xiao Z; Zhang X; Li N; Sun T; Zhang J; Kang C; Fan S; Dai L; Liu X
    Cancer Cell Int; 2024 Feb; 24(1):78. PubMed ID: 38374122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
    Guo H; Zhang S; Zhang B; Shang Y; Liu X; Wang M; Wang H; Fan Y; Tan K
    Front Immunol; 2023; 14():1202324. PubMed ID: 37457742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
    Chen J; Chen X; Li T; Wang L; Lin G
    Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
    Yang Y; Xiao W; Liu R; Gao L; Chen J; Kan H
    J Immunol Res; 2022; 2022():4983532. PubMed ID: 36405011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.